<DOC>
	<DOCNO>NCT01244490</DOCNO>
	<brief_summary>For child adolescent , SPD503 compare placebo treatment Attention-Deficit/Hyperactivity Disorder ( ADHD ) .</brief_summary>
	<brief_title>Efficacy Safety Extended-release Guanfacine Hydrochloride Children Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>1 . Male female , age 6 17 year time consent/assent Screening ( Visit 1 ) . 2 . Subject 's parent legally authorise representative ( LAR ) must provide signature informed consent , must documentation assent ( applicable ) subject indicate subject aware investigational nature study require procedure restriction accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guidance E6 , applicable regulation complete study related procedure Screening ( Visit 1 ) . 3 . Subject meet Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) criteria primary diagnosis ADHD , combine subtype , hyperactive/impulsive subtype , inattentive subtype base detailed psychiatric evaluation use Kiddie Schedule Affective Disorders Schizophrenia Present Lifetime version ( KSADSPL ) . 4 . Subject minimum ADHDRSIV total score 32 Baseline ( Visit 2 ) . 5 . Subject minimum CGIS score 4 Baseline ( Visit 2 ) . 6 . Subject function ageappropriate level intellectually , judge Investigator . 7 . Subject parent/LAR understand , willing , able , likely fully comply study procedure restriction define protocol . 8 . Subject able swallow intact tablet capsule . 9 . Subject female childbearing potential ( FOCP ) , define great equal 9 year age &lt; 9 year age menarchal , must negative serum beta Human Chorionic Gonadotropin ( hCG ) pregnancy test Screening ( Visit 1 ) negative urine pregnancy test Baseline ( Visit 2 ) agree comply applicable contraceptive requirement protocol . 10 . Subject supine stand blood pressure ( BP ) measurement within 95th percentile age , sex , height 1 . Subject current , control ( require prohibit medication behavioural modification program ) uncontrolled , comorbid psychiatric diagnosis [ except oppositional defiant disorder ( ODD ) ] , include severe comorbid Axis II disorder severe Axis I disorder post traumatic stress disorder ( PTSD ) , bipolar illness , psychosis , pervasive developmental disorder , obsessivecompulsive disorder ( OCD ) , substance abuse disorder , symptomatic manifestation lifetime history bipolar illness , psychosis conduct disorder , opinion Investigator , contraindicate treatment SPD503 STRATTERA confound efficacy safety assessment . 2 . Subject wellcontrolled current medication , acceptable tolerability , parent/caregiver object current medication . 3 . Subject condition illness include clinically significant abnormal Screening ( Visit 1 ) laboratory value , opinion Investigator , represent inappropriate risk subject and/or could confound interpretation study . Mild stable asthma treat without use beta2 agonist exclusionary . 4 . Subject known history presence structural cardiac abnormality , cardiovascular cerebrovascular disease , serious heart rhythm abnormality , syncope , tachycardia , cardiac conduction problem ( eg , clinically significant heart block QT interval prolongation ) , exerciserelated cardiac event include syncope pre syncope , clinically significant bradycardia . 5 . Subject know family history sudden cardiac death , ventricular arrhythmia , QT prolongation . 6 . Subjects orthostatic hypotension know history hypertension . 7 . Subject glaucoma . 8 . Subject clinically significant ECG finding judge Investigator consideration central ECG laboratory 's interpretation . 9 . Subject history seizure disorder ( single childhood febrile seizure occur age 3 year ) presence serious tic disorder include Tourette 's Syndrome . 10 . Current use prohibit medication medication , include monoamine oxidase inhibitor , herbal supplement , affect BP heart rate potent CYP2D6 inhibitor , medication know prolong QT/QTc interval , medication low seizure threshold , pressor agent , beta2 agonist , medication affect noradrenaline , medication central nervous system ( CNS ) effect affect cognitive performance , sedate antihistamine decongestant sympathomimetics ( inhaled bronchodilator permit ) history chronic use sedate medication [ ie , antihistamine ] ) violation protocol specify washout criterion Baseline ( Visit 2 ) . 11 . Subject history alcohol substance abuse dependence , define DSMIV ( exception nicotine ) within last 6 month . 12 . Subject take another investigational product within 30 day prior Baseline ( Visit 2 ) . 13 . Subject significantly overweight base Center Disease Control Prevention Body Mass Index ( BMI ) forage gender specific chart Screening ( Visit 1 ) . Significantly overweight define BMI &gt; 95th percentile . 14 . Children age 6 12 year body weight less 25kg adolescent age 13 17 year body weight less 34kg great 91kg Screening ( Visit 1 ) . 15 . Subject know suspected allergy , hypersensitivity , clinically significant intolerance guanfacine hydrochloride atomoxetine hydrochloride , component find SPD503 STRATTERA . 16 . Clinically important abnormality drug alcohol screen ( exclude subject 's current ADHD stimulant applicable ) Screening ( Visit 1 ) 17 . Subject female pregnant currently lactate . 18 . Subject fail screen previously enrol study . 19 . Subject currently consider suicide risk opinion Investigator , previously make suicide attempt , prior history , currently demonstrate active suicide ideation . Subjects intermittent passive suicidal ideation necessarily exclude base assessment Investigator . 20 . History failure respond adequate trial Î±2agonist atomoxetine hydrochloride treatment ADHD ( consist appropriate dose adequate duration therapy opinion investigator ) . 21 . Subjects renal hepatic insufficiency .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ADHD</keyword>
</DOC>